New Approval for Metastatic Breast Cancer: Alpelisib

This past May, the FDA approved the targeted therapy alpelisib (Piqray) to treat certain hormone receptor-positive, HER2-negative breast cancers in postmenopausal women and in men. Up to 40 percent of people with metastatic hormone receptor-positive, HER2-negative breast cancer could be eligible to get the treatment, which targets a mutation on the PIK3CA gene. Join us on July 22 to hear from our speaker Adam Brufsky, MD, PhD about this new medicine, how to access it and some of the side effects that come with it.

Alpelisib is the first PI3K inhibitor approved for breast cancer. Learn more about the FDA approval.